In addition, the Immunoscore®, a metric that quantifies immune cell infiltration (particularly CD3+ and CD8+ cells) within tumors10–12, provides a more comprehensive characterization of the TME and highlights the significant prognostic value of tumor-infiltrating lymphocytes (TILs), regardless of cancer stage at diagnosis13,14. This evidence concerns the gene CD8A and cancer.